These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36908673)

  • 1. Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use-Patient Harms and Prescriber Responsibilities.
    Van Norman GA
    JACC Basic Transl Sci; 2023 Feb; 8(2):224-233. PubMed ID: 36908673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going?
    Joseph JN; Deaton D; Ehsan H; Bonanno MA
    J Health Life Sci Law; 2009 Jan; 2(2):73-108. PubMed ID: 19288889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
    Gilhooley M
    Am J Law Med; 2011; 37(2-3):258-77. PubMed ID: 21847881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.
    Klara K; Kim J; Ross JS
    J Gen Intern Med; 2018 May; 33(5):651-658. PubMed ID: 29484575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.
    Liu S; Mello MM; Kesselheim AS
    J Health Polit Policy Law; 2021 Jun; 46(3):487-504. PubMed ID: 33647951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ethical and legal problems arising from off-label use of medical devices and some solution recommendations].
    Ekmekçi PE; Arda B
    Turk Kardiyol Dern Ars; 2018 Jun; 46(4):318-325. PubMed ID: 29853702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
    O'Reilly J; Dalal A
    Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States v. Caronia: The increasing strength of commercial free speech and potential new emphasis on classifying off-label promotion as "false and misleading".
    Scheineson MJ; Cuevas G
    Food Drug Law J; 2013; 68(2):201-16, iii. PubMed ID: 24640469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.
    Kesselheim AS; Mello MM; Studdert DM
    PLoS Med; 2011 Apr; 8(4):e1000431. PubMed ID: 21483716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using price-volume agreements to manage pharmaceutical leakage and off-label promotion.
    Zhang H; Zaric GS
    Eur J Health Econ; 2015 Sep; 16(7):747-61. PubMed ID: 25193525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
    Schwartz LM; Woloshin S; Lu Z; Ross KM; Tessema FA; Peter D; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006073. PubMed ID: 31707825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
    Baker R
    BETA; 1998 Jul; ():8-9. PubMed ID: 11365570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label prescribing: a call for heightened professional and government oversight.
    Dresser R; Frader J
    J Law Med Ethics; 2009; 37(3):476-86, 396. PubMed ID: 19723258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rooting out institutional corruption to manage inappropriate off-label drug use.
    Rodwin MA
    J Law Med Ethics; 2013; 41(3):654-64. PubMed ID: 24088156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-Label Use of Medical Devices in Children.
    ;
    Pediatrics; 2017 Jan; 139(1):. PubMed ID: 28025239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.